We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Mettler-Toledo (MTD) in Q3 Earnings?
Read MoreHide Full Article
Mettler-Toledo International, Inc. (MTD - Free Report) is set to report third-quarter 2018 results on Nov 8.
The company topped the Zacks Consensus Estimate in three of the trailing four quarters while missed the same only once, recording an average positive earnings surprise of 0.73%.
In the last reported quarter, Mettler-Toledo reported adjusted earnings of $4.65 per share, which increased 18.6% on a year-over-year basis. The figure also outpaced the Zacks Consensus Estimate by 7 cents.
Net sales of $722 million surpassed the Zacks Consensus Estimate of $714.9 million and were also up 10.5% year over year.
The growth was driven by robust performance of Laboratory business across all geographies and benefits from the Biotix acquisition. Also, strong performance in China propelled growth.
For third-quarter 2018, the company anticipates local currency sales growth of 6%. Adjusted earnings are expected in the range of $4.97-$5.02 per share, up 14-15% year over year.
Notably, shares of Mettler-Toledo have lost 8.3% on a year-to-date basis against the industry’s growth of 4.3%.
Let’s see how things are shaping up for this announcement.
Key Factors to Consider
Mettler-Toledo’s sales growth remains very specific to its segmental performance. The company’s well performing Laboratory segment has been driving top-line growth over the past few years.
We remain optimistic about the positive contributions from Biotix acquisition, which should continue to benefit the laboratory business’ sales figure in the quarter to be reported. Moreover, its strong product pipeline that includes robust analytical instruments, balances, auto-chem, to name a few, remains a positive for the to-be reported quarter.
Further, Spinnaker sales and marketing programs are likely to drive the top and bottom lines. Additionally, the company remains confident of its position in the European as well as Chinese market.
However, cost consolidation process related to product inspection business is likely to impact the company’s performance in the Industrial segment. Additionally, Mettler-Toledo’s Retail segment is likely to experience sluggish growth due to its lumpy nature.
Further, the U.S.-China trade war regarding tariff is a major concern for the company’s export-import activities in China.
What Our Model Says
According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has good chance of beating estimates if it also has a positive Earnings ESP. The Sell-rated stocks (Zacks Rank #4 or 5) are best avoided. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Mettler-Toledo currently has a Zacks Rank #3 and an Earnings ESP of -2.23%, making surprise prediction difficult.
Mettler-Toledo International, Inc. Price and EPS Surprise
Here are a few stocks worth considering as our model shows that these have the right combination of elements to deliver an earnings beat in the upcoming releases.
Adobe Systems Incorporated (ADBE - Free Report) has an Earnings ESP of +0.19% and carries a Zacks Rank #2.
Five9 (FIVN - Free Report) has an Earnings ESP of +5.88% and a Zacks Rank #3.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
What's in Store for Mettler-Toledo (MTD) in Q3 Earnings?
Mettler-Toledo International, Inc. (MTD - Free Report) is set to report third-quarter 2018 results on Nov 8.
The company topped the Zacks Consensus Estimate in three of the trailing four quarters while missed the same only once, recording an average positive earnings surprise of 0.73%.
In the last reported quarter, Mettler-Toledo reported adjusted earnings of $4.65 per share, which increased 18.6% on a year-over-year basis. The figure also outpaced the Zacks Consensus Estimate by 7 cents.
Net sales of $722 million surpassed the Zacks Consensus Estimate of $714.9 million and were also up 10.5% year over year.
The growth was driven by robust performance of Laboratory business across all geographies and benefits from the Biotix acquisition. Also, strong performance in China propelled growth.
For third-quarter 2018, the company anticipates local currency sales growth of 6%. Adjusted earnings are expected in the range of $4.97-$5.02 per share, up 14-15% year over year.
Notably, shares of Mettler-Toledo have lost 8.3% on a year-to-date basis against the industry’s growth of 4.3%.
Let’s see how things are shaping up for this announcement.
Key Factors to Consider
Mettler-Toledo’s sales growth remains very specific to its segmental performance. The company’s well performing Laboratory segment has been driving top-line growth over the past few years.
We remain optimistic about the positive contributions from Biotix acquisition, which should continue to benefit the laboratory business’ sales figure in the quarter to be reported. Moreover, its strong product pipeline that includes robust analytical instruments, balances, auto-chem, to name a few, remains a positive for the to-be reported quarter.
Further, Spinnaker sales and marketing programs are likely to drive the top and bottom lines. Additionally, the company remains confident of its position in the European as well as Chinese market.
However, cost consolidation process related to product inspection business is likely to impact the company’s performance in the Industrial segment. Additionally, Mettler-Toledo’s Retail segment is likely to experience sluggish growth due to its lumpy nature.
Further, the U.S.-China trade war regarding tariff is a major concern for the company’s export-import activities in China.
What Our Model Says
According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has good chance of beating estimates if it also has a positive Earnings ESP. The Sell-rated stocks (Zacks Rank #4 or 5) are best avoided. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Mettler-Toledo currently has a Zacks Rank #3 and an Earnings ESP of -2.23%, making surprise prediction difficult.
Mettler-Toledo International, Inc. Price and EPS Surprise
Mettler-Toledo International, Inc. Price and EPS Surprise | Mettler-Toledo International, Inc. Quote
Stocks That Warrant a Look
Here are a few stocks worth considering as our model shows that these have the right combination of elements to deliver an earnings beat in the upcoming releases.
AMETEK (AME - Free Report) has an Earnings ESP of +1.69% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Adobe Systems Incorporated (ADBE - Free Report) has an Earnings ESP of +0.19% and carries a Zacks Rank #2.
Five9 (FIVN - Free Report) has an Earnings ESP of +5.88% and a Zacks Rank #3.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>